Abstract A004: HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients
2014 ◽
Vol 20
(18)
◽
pp. 4758-4767
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. e15176-e15176
◽
2020 ◽
Vol 69
(4)
◽
pp. 663-675
◽